Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice.
- 0
Gene-engineered CD34(+) hematopoietic stem and progenitor cells (HSPCs) can be utilized to generate an HIV-1-resistant immune system. Nevertheless, a sure threshold of transduced HSPCs is perhaps required for transplantation into mice for creating an HIV-resistant immune system.
On this examine, we mixed CCR5 knockdown by a extremely environment friendly microRNA (miRNA) lentivector with pretransplantation number of transduced HSPCs to acquire a reasonably pure inhabitants of gene engineered CD34(+) cells. Low-level transduction of HSPCs and subsequent sorting by circulate cytometry yielded >70% transduced cells.
Mice transplanted with these cells confirmed purposeful and protracted resistance to a CCR5-tropic HIV pressure: viral load was considerably decreased over months, and human CD4(+) T cells had been preserved. In a single mouse, viral mutations, ensuing presumably in a CXCR4-tropic pressure, overcame HIV resistance. Our outcomes recommend that HSPC-based CCR5 knockdown could result in environment friendly management of HIV in vivo.
We overcame a serious limitation of earlier HIV gene remedy in humanized mice wherein solely a proportion of the cells in chimeric mice in vivo are anti-HIV engineered. Our technique underlines the promising way forward for gene engineering HIV-resistant CD34(+) cells that produce a relentless provide of HIV-resistant progeny.
Lengthy-term central and effector SHIV-specific reminiscence T cell responses elicited after a single immunization with a novel lentivector DNA vaccine.
Prevention of HIV acquisition and replication requires lengthy lasting and efficient immunity. Given the state of HIV vaccine improvement, progressive vectors and immunization methods are urgently wanted to generate secure and efficacious HIV vaccines.
Right here, we developed a novel lentivirus-based DNA vector that doesn’t combine within the host genome and undergoes a single-cycle of replication. Viral proteins are constitutively expressed below the management of Tat-independent LTR promoter from goat lentivirus. We immunized six macaques as soon as solely with CAL-SHIV-IN- DNA utilizing mixed intramuscular and intradermal injections plus electroporation.
Antigen-specific T cell responses had been monitored for 47 weeks post-immunization (PI). PBMCs had been assessed straight ex vivo or after 6 and 12 days of in vitro tradition utilizing antigenic and/or homeostatic proliferation. IFN-γ ELISPOT was used to measure speedy cytokine secretion from antigen particular effector cells and from reminiscence precursors with excessive proliferative capability (PHPC).
The reminiscence phenotype and capabilities (proliferation, cytokine expression, lytic content material) of particular T cells had been examined utilizing multiparametric FACS-based assays. All immunized macaques developed lasting peripheral CD8+ and CD4+ T cell responses primarily in opposition to Gag and Nef antigens.
Throughout the major enlargement part, speedy effector cells in addition to growing numbers of proliferating cells with restricted effector capabilities had been detected which expressed markers of effector (EM) and central (CM) reminiscence phenotypes.
These responses contracted however then reemerged later in absence of antigen enhance. Sturdy PHPC responses comprising vaccine-specific CM and EM T cells that readily expanded and purchased speedy effector capabilities had been detected at 40/47 weeks PI. Altogether, our examine demonstrated {that a} single immunization with a replication-limited DNA vaccine elicited persistent vaccine-specific CM and EM CD8+ and CD4+ T cells with speedy and readily inducible effector capabilities, within the absence of ongoing antigen expression.
Immunogenicity of focused lentivectors.
To extend the security and probably efficacy of HIV-1 derived lentivectors (LVs) as an anti-cancer vaccine, we not too long ago developed the Nanobody (Nb) show know-how to focus on LVs to antigen presenting cells (APCs). On this examine, we prolong these knowledge with unique focusing on of LVs to traditional dendritic cells (DCs), that are believed to be the principle cross-presenting APCs for the induction of a TH1-conducted antitumor immune response.
The immunogenicity of those DC-subtype focused LVs was in comparison with that of broad tropism, common APC-targeted and non-infectious LVs. Intranodal immunization with ovalbumin encoding LVs induced proliferation of antigen particular CD4+ T cells, regardless of the LVs’ focusing on capacity.
Nevertheless, the cytokine secretion profile of the restimulated CD4+ T cells demonstrated that common APC focusing on induced an analogous TH1-profile because the broad tropism LVs whereas transduction of standard DCs alone induced an analogous and fewer potent TH1 profile because the non-infectious LVs. This commentary contradicts the speculation that standard DCs are crucial APCs and means that the activation of different APCs can also be significant.
Regardless of these variations, all focused LVs had been capable of stimulate cytotoxic T lymphocytes, be it to a lesser extent than broad tropism LVs. Moreover this induction was proven to be depending on sort I interferon for the focused and non-infectious LVs, however not for broad tropism LVs. Lastly we demonstrated that the APC-targeted LVs had been as potent in remedy as broad tropism LVs and as such ship on their promise as safer and efficacious LV-based vaccines.
Design of a novel integration-deficient lentivector know-how that includes genetic and posttranslational parts to focus on human dendritic cells.
As sentinels of the immune system, dendritic cells (DCs) play a necessary function in regulating mobile immune responses. One of many foremost challenges of creating DC-targeted therapies contains the supply of antigen to DCs with the intention to promote the activation of antigen-specific effector CD8 T cells.
With the objective of making antigen-directed immunotherapeutics that may be safely administered on to sufferers, Immune Design has developed a platform of novel integration-deficient lentiviral vectors that focus on and ship antigen-encoding nucleic acids to human DCs.
This platform, termed ID-VP02, makes use of a novel genetic variant of a Sindbis virus envelope glycoprotein with posttranslational carbohydrate modifications together with Vpx, a SIVmac viral accent protein, to attain environment friendly focusing on and transduction of human DCs. As well as, ID-VP02 incorporates security options in its design that embrace two redundant mechanisms to render ID-VP02 integration-deficient.
Right here, we describe the traits that enable ID-VP02 to particularly transduce human DCs, and the advances that ID-VP02 brings to traditional third-generation lentiviral vector design in addition to exhibit upstream manufacturing yields that can allow manufacturing feasibility research to be performed.
Cell-cell transmission of VSV-G pseudotyped lentivector particles
Many replicating viruses, together with HIV-1 and HTLV-1, are effectively transmitted from the cell floor of actively contaminated cells upon contact with bystander cells. In a earlier examine, we reported the extended cell floor retention of VSV-G replication-deficient pseudotyped lentivector previous to endocytic entry. Nevertheless, the competing kinetics of cell floor versus dissociation, neutralization or direct switch to different cells have acquired comparatively little consideration.
Right here we exhibit that the relative effectivity of cell-cell floor transmission can outpace “cell-free” transduction at limiting vector enter. This coincides with the extended half-life of cell certain vector however happens, in contrast to HTLV-1, with out proof for particle aggregation.
C1orf109 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV707955 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf109 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707959 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf116 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV707961 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf116 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707965 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf124 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV707967 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf124 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV707971 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf126 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV706029 | ABM | 1.0 ug DNA | EUR 540 |
C1orf126 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV706033 | ABM | 1.0 ug DNA | EUR 540 |
C1orf212 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV706299 | ABM | 1.0 ug DNA | EUR 540 |
C1orf212 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV706303 | ABM | 1.0 ug DNA | EUR 540 |
C1orf132 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720023 | ABM | 1.0 ug DNA | Ask for price |
C1orf132 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720027 | ABM | 1.0 ug DNA | Ask for price |
C1orf134 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720029 | ABM | 1.0 ug DNA | Ask for price |
C1orf134 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720033 | ABM | 1.0 ug DNA | Ask for price |
C1orf138 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720035 | ABM | 1.0 ug DNA | Ask for price |
C1orf138 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720039 | ABM | 1.0 ug DNA | Ask for price |
C1orf145 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720041 | ABM | 1.0 ug DNA | Ask for price |
C1orf145 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720045 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720047 | ABM | 1.0 ug DNA | Ask for price |
C1orf148 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720051 | ABM | 1.0 ug DNA | Ask for price |
C1orf195 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720053 | ABM | 1.0 ug DNA | Ask for price |
C1orf195 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720057 | ABM | 1.0 ug DNA | Ask for price |
C1orf196 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720059 | ABM | 1.0 ug DNA | Ask for price |
C1orf196 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720063 | ABM | 1.0 ug DNA | Ask for price |
C6orf100 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720113 | ABM | 1.0 ug DNA | Ask for price |
C6orf100 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720117 | ABM | 1.0 ug DNA | Ask for price |
C6orf183 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720119 | ABM | 1.0 ug DNA | Ask for price |
C6orf183 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720123 | ABM | 1.0 ug DNA | Ask for price |
C9orf107 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720155 | ABM | 1.0 ug DNA | Ask for price |
C9orf107 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720159 | ABM | 1.0 ug DNA | Ask for price |
C9orf118 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720161 | ABM | 1.0 ug DNA | Ask for price |
C9orf118 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720165 | ABM | 1.0 ug DNA | Ask for price |
C9orf141 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720167 | ABM | 1.0 ug DNA | Ask for price |
C9orf141 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720171 | ABM | 1.0 ug DNA | Ask for price |
C1orf143 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV758175 | ABM | 1.0 ug DNA | Ask for price |
C1ORF233 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV758177 | ABM | 1.0 ug DNA | Ask for price |
C1ORF233 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV758181 | ABM | 1.0 ug DNA | Ask for price |
C6ORF228 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV758219 | ABM | 1.0 ug DNA | EUR 547.2 |
C6ORF228 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV758223 | ABM | 1.0 ug DNA | EUR 547.2 |
C1orf137 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV758165 | ABM | 1.0 ug DNA | Ask for price |
C1orf137 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV758169 | ABM | 1.0 ug DNA | Ask for price |
C1orf143 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV758171 | ABM | 1.0 ug DNA | Ask for price |
C6orf185 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV814485 | ABM | 1.0 ug DNA | EUR 540 |
C6orf185 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV814489 | ABM | 1.0 ug DNA | EUR 540 |
C6orf150 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV815067 | ABM | 1.0 ug DNA | EUR 540 |
C6orf150 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV815071 | ABM | 1.0 ug DNA | EUR 540 |
C9orf127 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV815229 | ABM | 1.0 ug DNA | EUR 540 |
C9orf127 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV815233 | ABM | 1.0 ug DNA | EUR 540 |
C6orf122 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV815247 | ABM | 1.0 ug DNA | EUR 540 |
C6orf122 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV815251 | ABM | 1.0 ug DNA | EUR 540 |
C1orf161 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV815451 | ABM | 1.0 ug DNA | EUR 540 |
C1orf161 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV815455 | ABM | 1.0 ug DNA | EUR 540 |
C1orf104 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV815475 | ABM | 1.0 ug DNA | EUR 540 |
C1orf104 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV815479 | ABM | 1.0 ug DNA | EUR 540 |
C1orf104 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV815511 | ABM | 1.0 ug DNA | EUR 540 |
C1orf104 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV815515 | ABM | 1.0 ug DNA | EUR 540 |
C6orf168 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810681 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf168 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810685 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf142 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810861 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf142 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810865 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf190 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810897 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf190 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810901 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf102 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV811083 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf102 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811087 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf156 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV811335 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf156 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811339 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf125 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV811425 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf125 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811429 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf168 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV811449 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf168 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV811453 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf134 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV812229 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf134 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV812233 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf102 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV812337 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf102 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV812341 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf146 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV812415 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf146 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV812419 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf150 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV812571 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf150 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV812575 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf134 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV812769 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf134 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV812773 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf182 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV812931 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf182 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV812935 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf142 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV809265 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf142 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV809269 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf183 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV809343 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf103 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV809487 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf115 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV809673 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf115 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV809677 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf125 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV809763 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf125 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV809767 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf149 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV809829 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf149 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV809833 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf105 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV809883 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf105 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV809887 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf107 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810021 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf107 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810025 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf217 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810033 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf217 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810037 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf163 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810195 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf163 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810199 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf211 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810231 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf211 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810235 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf218 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810243 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf218 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810247 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf157 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV814125 | ABM | 1.0 ug DNA | EUR 540 |
C1orf157 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV814129 | ABM | 1.0 ug DNA | EUR 540 |
C1orf175 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV814209 | ABM | 1.0 ug DNA | EUR 540 |
C1orf175 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV814213 | ABM | 1.0 ug DNA | EUR 540 |
C6orf190 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV814239 | ABM | 1.0 ug DNA | EUR 540 |
C6orf190 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV814243 | ABM | 1.0 ug DNA | EUR 540 |
C6orf184 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV814341 | ABM | 1.0 ug DNA | EUR 540 |
C6orf184 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV814345 | ABM | 1.0 ug DNA | EUR 540 |
C6orf182 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810465 | ABM | 1.0 ug DNA | EUR 379.2 |
C6orf182 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810469 | ABM | 1.0 ug DNA | EUR 379.2 |
C1orf227 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV795069 | ABM | 1.0 ug DNA | EUR 547.2 |
C1orf128 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV809193 | ABM | 1.0 ug DNA | EUR 379.2 |
C9orf171 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV791197 | ABM | 1.0 ug DNA | EUR 540 |
C10orf118 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV702213 | ABM | 1.0 ug DNA | EUR 540 |
C10orf118 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV702217 | ABM | 1.0 ug DNA | EUR 540 |
C14orf159 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV708141 | ABM | 1.0 ug DNA | EUR 379.2 |
C14orf159 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708145 | ABM | 1.0 ug DNA | EUR 379.2 |
C20orf141 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV708231 | ABM | 1.0 ug DNA | EUR 379.2 |
C20orf141 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV708235 | ABM | 1.0 ug DNA | EUR 379.2 |
C10orf100 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720173 | ABM | 1.0 ug DNA | Ask for price |
C10orf100 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720177 | ABM | 1.0 ug DNA | Ask for price |
C10orf101 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720179 | ABM | 1.0 ug DNA | Ask for price |
C10orf101 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720183 | ABM | 1.0 ug DNA | Ask for price |
C10orf102 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720185 | ABM | 1.0 ug DNA | Ask for price |
C10orf102 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720189 | ABM | 1.0 ug DNA | Ask for price |
C14orf144 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720233 | ABM | 1.0 ug DNA | Ask for price |
C14orf144 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720237 | ABM | 1.0 ug DNA | Ask for price |
C14orf164 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720239 | ABM | 1.0 ug DNA | Ask for price |
C14orf164 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720243 | ABM | 1.0 ug DNA | Ask for price |
C20orf168 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720317 | ABM | 1.0 ug DNA | Ask for price |
C20orf168 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720321 | ABM | 1.0 ug DNA | Ask for price |
C20orf187 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720323 | ABM | 1.0 ug DNA | Ask for price |
C20orf187 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720327 | ABM | 1.0 ug DNA | Ask for price |
C21orf118 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV720347 | ABM | 1.0 ug DNA | Ask for price |
C21orf118 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV720351 | ABM | 1.0 ug DNA | Ask for price |
C10orf137 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV704457 | ABM | 1.0 ug DNA | EUR 540 |
C10orf137 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV704461 | ABM | 1.0 ug DNA | EUR 540 |
C20orf132 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV704727 | ABM | 1.0 ug DNA | EUR 540 |
C20orf132 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV704731 | ABM | 1.0 ug DNA | EUR 540 |
C14orf157 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV758291 | ABM | 1.0 ug DNA | EUR 547.2 |
C14orf157 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV758295 | ABM | 1.0 ug DNA | EUR 547.2 |
C10orf115 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV758255 | ABM | 1.0 ug DNA | EUR 547.2 |
C10orf115 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV758259 | ABM | 1.0 ug DNA | EUR 547.2 |
C10orf135 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV758261 | ABM | 1.0 ug DNA | EUR 547.2 |
C10orf135 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV758265 | ABM | 1.0 ug DNA | EUR 547.2 |
C17ORF110 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV758321 | ABM | 1.0 ug DNA | EUR 547.2 |
These research recommend that cell-surface attachment stabilizes particles and alters neutralization kinetics. Our experiments present novel perception into the underexplored cell-cell transmission of pseudotyped particles.
